Citizens has upgraded Stryker Corp (SYK) to Market Outperform from Market Perform as of December 18, 2025. The current price of the stock is $356.16.
This upgrade reflects a more optimistic view on Stryker's prospects, possibly indicating improved fundamentals or better-than-expected business performance. Stryker Corp, headquartered in Portage, Michigan, is a leading medical technology company that provides products and services aimed at enhancing patient and healthcare outcomes. The firm employs approximately 53,000 people and operates in several segments, including MedSurg, Neurotechnology, and Orthopaedics.
As of December 1, 2025, the company has a market capitalisation of $135.8 billion, a trailing twelve-month price-to-earnings ratio of 46.13, and an earnings per share of 7.62. The dividend yield stands at 99.8%. Upcoming earnings are scheduled for July 29, 2026, with an estimated EPS of $3.51 and revenue of $6.6 billion.
Analyst ratings, while helpful, should be considered alongside various factors such as company fundamentals, competitive positioning, and industry trends. Recent analyst actions include an upgrade from Citizens and maintained ratings from Truist Securities and Citigroup, reflecting a consensus of 11 Strong Buy, 15 Buy, and 10 Hold ratings among 36 total analysts. Such decisions reflect the evolving sentiment surrounding Stryker's performance and market position.